CDK12 and neoplasm: Additional genomic predictive biomarkers for response to immunotherapy have also recently been identified; mutations within cyclin-dependent kinase 12 (CDK12), a tumour suppressor protein with roles connected to genomic stability [348], have also been demonstrated to lead to the creation of neoantigens [349].